May 26, 2026 – Jiangxi Kvvit Pharmaceutical Co., Ltd. (hereinafter referred to as “Kvvit”), a subsidiary of QF Pharmaceutical Group, announced that it has entered into an exclusive license and collaboration agreement with German pharmaceutical company Merz Therapeutics GmbH for Inbrija® (generic name: levodopa inhalation powder) and its proprietary inhalation device. Kvvit has obtained exclusive development and commercialization rights for the product in Chinese mainland, Hong Kong and Macao for the intermittent management of OFF episodes in adult patients with Parkinson’s disease.
As the strategic global BD consulting advisor for Kvvit Pharma, Angine BD team spent nearly ten months by conducting the due diligence and negotiating transaction terms based on Kvvit's robust layout across central nervous system (CNS) therapies, ultimately facilitating Kvvit Pharma’s landmark collaboration with Merz with in-licensing of Merz’s flagship asset Inbrija. As the world’s first approved inhalable levodopa for intermittent management of Parkinson’s OFF episodes, Inbrija delivers rapid therapeutic onset within 10 minutes, filling unmet clinical gaps associated with slow onset of oral levodopa and invasive administration of subcutaneous apomorphine.
Under the agreement, Merz Therapeutics will receive an upfront payment, in addition to development and commercial milestone payments, as well as tiered supply and royalty arrangements linked to commercial performance in the territory.
About Inbrija® (levodopa inhalation powder)
Inbrija® is an U.S. Food and Drug Administration (2018) and European Medicines Agency (2019) approved, inhaled prescription levodopa medication indicated for the intermittent treatment of episodic motor fluctuations (OFF episodes) in adult patients with Parkinson’s disease (PD) treated with a levodopa/dopa-decarboxylase inhibitor4. As INBRIJA® is delivered directly to the lung, absorption of the medicine is not affected by meals or other PD-associated conditions affecting the gastrointestinal tract that can impact oral medications.4
About Merz Therapeutics
Merz Therapeutics GmbH is dedicated to delivering better outcomes for more patients. With science as its foundation and the patient experience as its focus, the company relentlessly pursues innovative treatments and partnerships to address unmet needs in movement disorders, neurodegenerative conditions, liver disease, and other health conditions that severely impact patients’ quality of life.
Merz Therapeutics is headquartered in Frankfurt am Main, Germany, and is active in more than 80 countries. Merz Therapeutics GmbH is part of the Merz Group, a privately held, family-owned company with a 117-year legacy. With passion and purpose, Merz Therapeutics continues to advance care in specialty neurology in ways that benefit both patients and society.
About Kvvit
Jiangxi Kvvit Pharmaceutical Co., Ltd., established in 2021, is a controlled subsidiary of QF Pharmaceutical Group Co., Ltd. It has been recognized as a National High-Tech Enterprise, a Jiangxi Provincial Enterprise Technology Center, and a Potential Gazelle Enterprise of Jiangxi Province. The company has built a global, full-chain innovation and R&D system, focusing on core therapeutic areas such as the central nervous system, anti-infectives, antineoplastic agents, and digestive systems. It has a presence in nearly 30 countries and regions, including the United States, East Asia, ASEAN, the Middle East, North Africa, and South America. Upholding the mission of “continuously providing outstanding healthcare service for the world,” Kvvit is dedicated to becoming a trusted and innovative pharmaceutical enterprise.
About Angine Bio
Founded in May 2017 and headquartered in Hangzhou, Zhejiang Province, Angine Bio has set up partner offices across the United States, Europe, Japan, Singapore, South Korea, Israel and India. As a technology-focused service provider specializing in cross-border biopharmaceutical business solutions and international technology transfer, the Company operates its proprietary digital global healthcare internationalization platform (www.angineglobal.com). Backed by in-house think tank specialists and worldwide collaborative partners, Angine Bio leverages platform-based industry expertise and big data to deliver niche professional services: it devises cross-border expansion strategies and localized market entry roadmaps for domestic life science clients going global; meanwhile, it provides customized in-licensing services for overseas innovative assets and professional support for out-licensing of China-originated pipeline drugs, outbound investment planning and localized overseas commercialization for domestic innovators.
If you have the innovative drug product which would like to explore the China market business opportunities via BD partnership, you can write the email via leoluo@anginebio.com.
